Press Releases

pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) Jul 27, 2016 Incremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit Read more
Data Shows pSivida's Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy Jul 20, 2016 Data Presented at 2016 Annual Meeting & Exposition of the Controlled Release Society Read more
pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility Jul 15, 2016 Plan to Facilitate Product Development and Reduce Operating Expenses Read more
Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve Jul 14, 2016 Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology Read more
pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting Jul 08, 2016 WATERTOWN, Mass. , July 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that pSivida's Dr. Catherine Kelly will present a poster and oral presentation on "The Controlled Read more
pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD Jul 05, 2016 Promising Results for Potential Sustained Treatment of Wet AMD Using a TKI Read more
pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results May 05, 2016 WATERTOWN, Mass. , May 05, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its third fiscal quarter ended March 31, Read more
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics May 04, 2016 WATERTOWN, Mass. , May 04, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , president and CEO, will present "Changing the Treatment Paradigm Read more
pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe May 02, 2016 WATERTOWN, Mass. , May 02, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the European Commission granted orphan medicinal product designation to Medidur™ for Read more
pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information Apr 27, 2016 WATERTOWN, Mass. , April 27, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2016 will be released after Read more
pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention Mar 24, 2016 WATERTOWN, Mass. , March 24, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the company will be presenting at the Sidoti Spring 2016 Emerging Growth Convention at Read more
Additional Favorable Six-Month Safety Results for pSivida's Medidur™ for Posterior Uveitis Mar 15, 2016 Small Average Increase in IOP Relative to Control Comparable Percentage Treated with Eye Drops for Elevated IOP WATERTOWN, Mass. , March 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye Read more
pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results Feb 08, 2016 WATERTOWN, Mass. , Feb. 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its second fiscal quarter ended Read more
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information Feb 01, 2016 WATERTOWN, Mass. , Feb. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2016 will be released after Read more
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9 Jan 28, 2016 WATERTOWN, Mass. , Jan. 28, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drugs for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 18 th Annual Bio CEO & Investor Conference, Read more
pSivida Closes $17.8 Million Offering Jan 13, 2016 WATERTOWN, Mass. , Jan. 13, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the closing yesterday of the underwritten public offering of 4,440,000 shares of its common Read more
pSivida Announces Pricing of $16 Million Public Offering of Common Stock Jan 07, 2016 WATERTOWN, Mass. , Jan. 07, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a Read more
pSivida Announces Proposed Public Offering of Common Stock Jan 06, 2016 WATERTOWN, Mass. , Jan. 06, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it intends to offer and sell shares of its common stock in a proposed underwritten Read more
pSivida Plans Medidur™ EU Marketing Approval Application Based on Single Phase 3 Clinical Trial Dec 28, 2015 WATERTOWN, Mass. , Dec. 28, 2015 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it plans to file for EU marketing approval of Medidur™ for chronic non-infectious Read more
pSivida's Medidur™ Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001) Dec 22, 2015 Statistical Significance in Improvement in Visual Acuity and Reduction in Systemic Therapy Medidur™, pictured below the pencil, is an injectable micro-insert designed to treat posterior uveitis. Injected into the back of the eye, it provides sustained release of 0.18 mg of a corticosteroid Read more

pSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001)

Jul 27, 2016

Data Shows pSivida's Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy

Jul 20, 2016

pSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility

Jul 15, 2016

Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve

Jul 14, 2016

pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting

Jul 08, 2016

pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD

Jul 05, 2016